摘要
目的研究探讨阿奇霉素治疗小儿支原体感染肺炎并变异性咳嗽的安全性。方法本次研究以2017年1月至2018年6月收治的80例小儿支原体感染肺炎并变异性咳嗽患者为研究对象,随机分为对照组和观察组各40例,对照组给予红霉素治疗,观察组给予阿奇霉素治疗,分析阿奇霉素治疗的价值,并对比两组的不良反应发生情况,症状消失时间等指标。结果观察组不良反应少于对照组,症状消失时间少于对照组,肝功能指标优于对照组,观察组的有效率为95.0%,对照组的为82.5%,观察组不良反应的发生率为5.0%,对照组不良反应的发生率为12.5%,差异有统计学意义(P<0.05)。结论对小儿支原体感染肺炎并变异性咳嗽患者采取阿奇霉素治疗,效果显著,可以减少对肝功能的损伤,减少症状消失时间,且安全性较高,不良反应少,可以提高治疗的依从性,值得在今后的治疗中推广。
Objective To investigate the safety of azithromycin in the treatment of mycoplasma pneumonia and variant cough in children. Methods The study in January 2017 to June 2018 80 cases of children were treated with mycoplasma pneumonia infection and variability in patients with cough as the research object, each 40 cases were randomly divided into control group and observation group, control group given erythromycin treatment, the observation group was given azithromycin treatment, the analysis of the value of azithromycin treatment, and compared two groups of adverse reactions occur, symptoms disappear time and so on. Results The effective rate of the observation group was 95.0%, that of the control group was 82.5%. The incidence of adverse reactions in the observation group was 5.0%, and that of the control group was 12.5%. The difference was statistically significant (P<0.05). Conclusion Azithromycin treatment for children with mycoplasma pneumoniae infection and variant cough has significant effect, can reduce the damage to liver function, reduce the time for symptoms to disappear, and has higher safety and fewer adverse reactions, can improve the compliance of treatment, and is worth promoting in the future treatment.
作者
高小
Gao Xiao(Department of Pediatrics, the Fifth Hospital of Huangshi City, Hubei Province, Huangshi, Hubei, 435005, China)
出处
《当代医学》
2019年第10期80-82,共3页
Contemporary Medicine
